AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

AB-101 is an off-the shelf, allogeneic cell product made of "natural killer" cells, also
called NK cells. White blood cells are part of the immune system and NK cells are a type
of white blood cell that are known to kill cancer cells.

This clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of
B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as
follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab
(including the DLBCL specific cohort) or in combination with bendamustine and rituximab;
2) to evaluate the potential clinical activity of AB-101 when given in combination with
rituximab or in combination with bendamustine and rituximab (combination cohorts only);
and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2
is to determine whether AB-101 in combination with rituximab or in combination with
bendamustine and rituximab has anti-cancer activity in patients.

Patients will be assigned to receive either AB-101 alone as monotherapy, in combination
with rituximab (including DLBCL specific cohort) or in combination with bendamustine and
rituximab. All patients will receive at least 1 treatment cycle of AB-101, followed by
scheduled assessments of overall health and tumor response. Patients receiving AB-101 in
combination with rituximab may receive up to 3 additional cycles of treatment. Patients
receiving AB-101 in combination with bendamustine and rituximab may receive up to 5
additional cycles of treatment. Patients enrolled into the DLBCL specific cohort
receiving AB-101 in combination with rituximab may receive up to 3 cycles of treatment.

Treatment Sites in Georgia